Merck's Keynote Clinical Trials are studying a way to treat cancer through immunotherapy-which may help the body's immune system fight cancer. The investigational immunotherapy used in the Keynote Trials is pembrolizumab, also known as MK-3475, a PD-1 blocking antibody.
Oncology immunotherapy is a type of cancer treatment designed to work with the body's natural defenses to fight the cancer. These treatments are engineered to allow your immune system to help recognize harmful tumor cells and destroy them.
The immune system sends certain types of cells, called T cells, throughout your body to detect and fight infections and diseases. Cancer cells can disguise themselves from your immune system, and when your immune system doesn't recognize the cancer cells, these harmful cells can grow.
Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.